Literature DB >> 21124252

Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy.

Taiichi Hikichi1, Hideo Ohtsuka, Makoto Higuchi, Takuro Matsushita, Hiroko Ariga, Shoko Kosaka, Reiko Matsushita, Kimitaka Takami.   

Abstract

PURPOSE: The purpose of this study was to determine the factors predictive of visual acuity (VA) outcomes 1 year after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy.
METHODS: We prospectively studied 220 eyes of 210 Japanese patients with polypoidal choroidal vasculopathy treated with primary application of PDT. A stepwise logistic regression model was used to estimate the independent factors predictive of better VA and improvement of VA 1 year after the primary PDT.
RESULTS: Visual acuities at the various follow-up evaluations improved significantly compared with baseline (P = 0.001 for all comparisons). The VA improved and decreased more than 0.3 logarithm of minimum angle of resolution unit 1 year after the primary PDT in 55 (25%) and 21 (10%) eyes, respectively. Stepwise logistic regression analysis showed that younger age, smaller greatest linear dimension, better baseline VA, and less baseline hemorrhage were significant and independent factors predictive of better VA 1 year after PDT, and younger age, smaller greatest linear dimension, better baseline VA, less hemorrhaging, and the presence of a serous macular detachment at baseline were significant and independent factors predictive of VA improvement.
CONCLUSION: Photodynamic therapy stabilized eyes anatomically and functionally. Clinical characteristics at baseline were predictors of favorable VA outcomes after PDT. These findings may help establish the strategy of treatment for polypoidal choroidal vasculopathy.

Entities:  

Mesh:

Year:  2011        PMID: 21124252     DOI: 10.1097/IAE.0b013e3181fecda9

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

1.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

2.  Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.

Authors:  Meng Zhao; Hai-Ying Zhou; Jun Xu; Feng Zhang; Wen-Bin Wei; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

3.  Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.

Authors:  M Ho; E C F Lo; A L Young; D T L Liu
Journal:  Eye (Lond)       Date:  2014-09-26       Impact factor: 3.775

4.  Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.

Authors:  Taiichi Hikichi
Journal:  BMC Ophthalmol       Date:  2015-04-10       Impact factor: 2.209

Review 5.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

6.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

7.  Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy.

Authors:  Taiichi Hikichi; Makoto Higuchi; Takuro Matsushita; Shoko Kosaka; Reiko Matsushita; Kimitaka Takami; Hideo Ohtsuka; Hirokuni Kitamei; Shoko Shioya
Journal:  Br J Ophthalmol       Date:  2013-02-21       Impact factor: 4.638

8.  Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Rei Nemoto; Masahiro Miura; Takuya Iwasaki; Hiroshi Goto
Journal:  Clin Ophthalmol       Date:  2012-10-08

Review 9.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10

10.  Systemic steroids as an aid to the management of Idiopathic Polypoidal Choroidal Vasculopathy (IPCV): A descriptive analysis.

Authors:  Aditya Sudhalkar; Divya Balakrishnan; Subhadra Jalali; Raja Narayanan
Journal:  Saudi J Ophthalmol       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.